SUGALIFE-S tab
MRP: 2
Packaging: 10X10
Pack Type: tablet
Composition:
Gliclazide IP 60mg (as Sustained Release Form) Sitagliptin Phosphate Monohydrate IP Sitagliptin 100mg
Indication:
for the treatment of Type 2 Diabetes Mellitus in adults. It helps to control blood glucose levels by enhancing insulin secretion, reducing hepatic glucose production, and improving insulin sensitivity. Suitable when diet, exercise, and monotherapy are insufficient.
Description:
This tablet is a combination of two oral antidiabetic agents: Gliclazide (a sulfonylurea) and Sitagliptin (a DPP-4 inhibitor).
It is used to manage Type 2 Diabetes Mellitus in adults. Gliclazide increases insulin secretion from the pancreas, while Sitagliptin enhances the body’s natural incretin system to improve insulin release and reduce blood glucose production.
Together, they provide dual glycemic control—both fasting and postprandial blood sugar levels—making it an effective once-daily oral therapy for managing type 2 diabetes in patients not adequately controlled by monotherapy.
Tags:
- Improves insulin secretion and sensitivity
- Controls both fasting and post-meal blood glucose
- Reduces risk of diabetes complications
- Convenient once-daily sustained release tablet
- Suitable for patients inadequately controlled by single agent
Usage Information
Dosage
Usual Dose: 1 tablet once daily, preferably with breakfast Swallow whole; do not crush or chew Follow your physician’s dosage recommendation Regular blood glucose monitoring advised
Side Effects
Hypoglycemia (especially if missed meals) Nausea or stomach upset Headache or dizziness Upper respiratory infections Rare: Pancreatitis or allergic skin reactions
Contraindications
Type 1 Diabetes or diabetic ketoacidosis Severe renal or hepatic impairment Pregnancy or lactation (unless advised by doctor) Known allergy to sulfonylureas or Sitagliptin Concurrent use of insulin (unless specifically advised)
Availability
Gliclazide Sitagliptin tablets, Gliclazide 60mg SR, Sitagliptin 100mg, dual antidiabetic medicine, DPP4 inhibitor with sulfonylurea, Type 2 diabetes combination therapy, diabetes sugar control tablets, Sitagliptin Gliclazide dose, sustained release gliclazide, sugar medicine with Sitagliptin